Financials

News Discussions Technicals Seasonals

0RK9 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Alligator Bioscience AB is a biotechnology company, which engages in the development of novel immuno-oncology drugs. The firm specializes in the development of tumor-directed immunotherapies. Its pipeline includes Mitazalimab, ATOR-1017, ALG.APV-527, Neo-X-Prime, and other research projects. The company was founded by Carl Arne Krister Borrebaeck in 2001 and is headquartered in Lund, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0RK9 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company